Kannan Thanikachalam MD | Roswell Park ...

Dr. Kannan Thanikachalam

Claim this profile

Thomas Hospital

Studies Pancreatic Cancer
Studies Pancreatic Carcinoma
7 reported clinical trials
19 drugs studied

Area of expertise

1

Pancreatic Cancer

Kannan Thanikachalam has run 3 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
BRCA1 positive
BRCA2 positive
2

Pancreatic Carcinoma

Kannan Thanikachalam has run 2 trials for Pancreatic Carcinoma. Some of their research focus areas include:

BRCA1 positive
BRCA2 positive
PALB2 positive

Affiliated Hospitals

Image of trial facility.

Thomas Hospital

Image of trial facility.

Mobile Infirmary Medical Center

Clinical Trials Kannan Thanikachalam is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.

Recruiting

1 award

Phase 2 & 3

20 criteria

Image of trial facility.

Olaparib

for Pancreatic Cancer

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Recruiting

0 awards

Phase 2

32 criteria

More about Kannan Thanikachalam

Clinical Trial Related

5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Kannan Thanikachalam has experience with

  • Gemcitabine
  • Fluorouracil
  • NovoTTF-200T
  • NovoTTF-100L(P)
  • Nab Paclitaxel
  • MFOLFIRINOX

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kannan Thanikachalam specialize in?

Is Kannan Thanikachalam currently recruiting for clinical trials?

Are there any treatments that Kannan Thanikachalam has studied deeply?

What is the best way to schedule an appointment with Kannan Thanikachalam?

What is the office address of Kannan Thanikachalam?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security